Ezogabine is a novel potassium-channel facilitator for adjunctive therapy of partial-onset seizures with a generally good safety profile.
May support adjunctive use in partial seizures; leaves open comparative efficacy and long-term data.
Ezogabine is a new drug for adjunctive therapy of partial-onset seizures with a novel mechanism of action. As a potassium-channel facilitator, it promotes membrane repolarization and thus opposes rapid repetitive discharges. Side effects are typical for antiepileptic drugs and the safety profile is good. Occasional instances of urinary difficulty may require surveillance.
No takes yet. Share an insight, caveat, or question.
Edward Faught (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: